已收盤 09-19 16:00:00 美东时间
+2.090
+1.67%
RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $181 price target.
09-19 22:23
This whale alert can help traders discover the next big trading opportunities. ...
09-19 01:35
The latest update is out from Sarepta Therapeutics ( ($SRPT) ). Sarepta Therape...
09-16 21:17
Ratings for Sarepta Therapeutics (NASDAQ:SRPT) were provided by 26 analysts in ...
09-07 01:01
Shares of Dyne Therapeutics (NASDAQ:DYN) fell 31% Tuesday after the company released new data from a clinical trial called DELIVER for its drug DYNE-251 in the treatment of Duchenne muscular dystrophy...
09-04 04:48
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
08-28 07:01
In the ever-evolving and intensely competitive business landscape, conducting a...
08-27 23:00
Sarepta Therapeutics's (NYSE:SRPT) short percent of float has fallen 9.25% sinc...
08-17 00:15
Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 28 analysts in the last...
08-16 00:00
With market volatility becoming a common phenomenon, Piper Sandler showcased eight "high-quality" defensive growth stocks in the biopharma space this week. Its comments came after a global sell-off of...
08-11 02:29